Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoBEAM-guided anti-EGFR withdrawal versus conventional first-line therapy in RAS/BRAF wild-type metastatic colorectal cancer
2018-004231-72Phase 4Active
- Sponsor
- Fundación IMABIS
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cetuximab and panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Fundación IMABIS. Primary endpoint: Median progression-free survival. Started Jun 2019; status: active.
02
Drugs
cetuximabpanitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-004231-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004231-72.